Jennifer R. Brown

New Capabilities

Led the Phase 3 AMPLIFY trial that supported the FDA approval

On February 20, 2026, the FDA approved venetoclax and acalabrutinib for chronic lymphocytic leukemia (CLL), the most common adult leukemia in Western countries, with roughly 23,000 new American cases each year. In a trial of 867 patients, 77% remained cancer-free at three years.

Updated May 29